Comparative cardiac toxicity in two treatment schedules of 5-FU/LV for colorectal carcinoma

被引:0
|
作者
Najam, Rahila [1 ]
Bano, Nusrat [1 ]
Mateen, Ahmed [2 ]
机构
[1] Univ Karachi, Fac Pharm, Dept Pharmacol, Karachi, Pakistan
[2] KIRAN, Karachi, Pakistan
关键词
Colorectal Carcinoma; Cardiac Toxicity; 5-FU; CPK; GOT; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR COMPLICATIONS; CANCER-THERAPY; 5-FLUOROURACIL; CARDIOTOXICITY; PATHOGENESIS; DIAGNOSIS; INFUSION; PATIENT;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of the study is evaluation and assessment of parameters of cardiac toxicity in patients subjected to 5-FU based chemotherapy. Cardiac morbidity is a reported outcome in different 5FU/LV regimens; however none of them are definite or proximate. The bimonthly regimen of high dose leucovorin is reported to be less toxic and more effective as compared to the monthly regimen of low dose leucovorin. We report the detailed assessment of few cardiac parameter of toxicity in patients of advanced colorectal carcinoma subjected to two Schedules of high and low dose Folinic Acid, 5-Fluorouracil, bolus and continuous infusion. The correlation of elevated cardiac biomarkers, angina and hypertension is comparatively assessed in patients with normal general status, hyperglycemia and known cardiac disorders subjected to two different 5FU based chemotherapeutic regimen.
引用
收藏
页码:1013 / 1022
页数:10
相关论文
共 50 条
  • [41] Palliative therapy for advanced biliary tract carcinoma with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV).
    Nehis, O
    Klump, B
    Gregor, M
    Porschen, R
    GASTROENTEROLOGY, 2000, 118 (04) : A523 - A523
  • [42] INTRAARTERIAL HEPATIC TREATMENT WITH CARBOPLATIN (CBDCA) AND 5-FLUOROURACIL (5-FU) IN METASTASES FROM COLORECTAL-CARCINOMA
    HIDALGO, OF
    REBOLLO, J
    VIEITEZ, JM
    BILBAO, I
    TANGCO, E
    ABUCHAIBE, O
    PARDO, F
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (01): : 30 - 33
  • [43] TREATMENT OF BASAL CELL CARCINOMA WITH 5-FLUOROURACIL (5-FU) OINTMENT
    REYMANN, F
    DERMATOLOGICA, 1970, 140 : 34 - &
  • [44] WEEKLY REGIMEN OF 5-FU VS 5-FU PLUS INTERMEDIATE DOSE FOLINIC ACID IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER
    MARTONI, A
    CRICCA, A
    GUARALDI, M
    COVIZZI, M
    FARRIS, A
    PANNUTI, F
    ANTICANCER RESEARCH, 1992, 12 (03) : 607 - 612
  • [45] CYCLOPHOSPHAMIDE PLUS 5-FU VERSUS 5-FU ALONE IN ADVANCED GASTRIC-CARCINOMA
    CHLEBOWSKI, RT
    WEINER, JM
    SILVERBERG, I
    GLASS, A
    BATEMAN, JR
    ONCOLOGY, 1985, 42 (03) : 141 - 143
  • [46] Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC - AIO-HEP-0116)
    Vogel, A.
    Wenzel, P.
    Folprecht, G.
    Schuett, P.
    Wege, H.
    Kretzschmar, A.
    Jacobasch, L.
    Ziegenhagen, N.
    Boeck, S.
    Kanzler, S.
    Mohm, J.
    Belle, S.
    Pink, D.
    Goetze, T. O.
    Goekkurt, E.
    Graeven, U.
    Schaaf, M.
    Kirstein, M.
    Saborowski, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S563 - S564
  • [47] A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma
    Ducreux, M
    Rougier, P
    Pignon, JP
    Douillard, JY
    Seitz, JF
    Bugat, R
    Bosset, JF
    Merouche, Y
    Raoul, JL
    Ychou, M
    Adenis, A
    Berthault-Cvitkovic, F
    Luboinski, M
    ANNALS OF ONCOLOGY, 2002, 13 (08) : 1185 - 1191
  • [48] ESCALATING BOLUS DOSE 5-FLUOROURACIL (5-FU) FOR METASTATIC COLORECTAL-CARCINOMA
    MAYER, RJ
    STEELE, GD
    FREI, E
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 415 - 415
  • [49] Long-term weekly treatment of advanced colorectal cancer (CRC) with fluorouracil (5-FU) and leucovorin (LV): 5 year-results of a multicentric phase II trial of 5-FU pharmacokinetic monitoring in 152 patients
    Lamezec, B
    Alleaume, C
    Gamelin, E
    Goudier, MJ
    Cailleux, PE
    DanquechinDorval, E
    Sire, M
    Maillet, ML
    Maigre, M
    Gesta, P
    Maillart, P
    Larra, F
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 726 - 726
  • [50] Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer:: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage
    Gamelin, E
    Boissdron-Celle, M
    Guérin-Meyer, V
    Delva, R
    Lortholary, A
    Genevieve, F
    Larra, F
    Ifrah, N
    Robert, J
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1105 - 1110